Figure 6

Brain Aβ levels. Treatment from 7–20 months significantly lowered total (FA extracted) Aβ40 and Aβ42 levels by 54% (*p = 0.04) and 61% (*p = 0.04), respectively ( A ). Soluble (DEA extracted) Aβ40 and Aβ42 fractions were also significantly reduced by 50% (***p = 0.0009) and 70% (*p = 0.019), respectively ( B ). Treatment in the 11–18 month study group significantly decreased total Aβ40 and Aβ42 brain levels by 69% (*p = 0.03) and 64% (*p = 0.026), respectively ( C ) and soluble Aβ40 and Aβ42 by 44% (*p = 0.047) and 53% (*p = 0.019) ( D ), as assessed by sandwich ELISA.